Lovén et al. found that in multiple myeloma, disruption of BRD4 (bromodomain-containing Protein-4) and mediator occupancy in an SE led to inhibition of tumor oncogenes, including MYC (44). This evidence concerns the gene BRD4 and plasma cell myeloma.